Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

ESMO 2016: From Disease Treatment to Patient Care


News provided by

European Society for Medical Oncology (ESMO)

13 Jun, 2016, 15:40 GMT

Share this article

Share toX

Share this article

Share toX

LUGANO, Switzerland and COPENHAGEN, Denmark, June 13, 2016 /PRNewswire/ --

ESMO 2016 Congress 

Bella Center, Copenhagen, Denmark  

7-11 October 2016 

MEDIA ALERT 

"Learning about the latest advances, discussing the clinical challenges and opportunities for today's oncologists and learning from each other to achieve a common goal - finding the best outcomes for cancer patients. You can find all this at the ESMO 2016 Congress." 

Fortunato Ciardiello, ESMO President and ESMO 2016 Congress President 

Nearly 2,900 abstracts were submitted for inclusion within the ESMO 2016 Congress, marking a 70% increase over the past six years and confirming the ESMO Congress as the leading oncology event in Europe.

With USA, Italy, Spain, France and Japan being the top five submitters, the ESMO 2016 Congress will be a truly international convention at which to learn about the latest advances in cancer, discuss clinical challenges and share best practices in order to improve patient treatment and care.

More than 19,000 participants from 130 countries worldwide are expected in Copenhagen, from professionals representing various oncology disciplines to healthcare policy makers, and from patient advocates and pharmaceutical companies to international media.

Congress programme highlights: 

  • 80 late-breaking abstracts submitted, with top submissions in colorectal and gastrointestinal cancers, non-small-cell lung cancer, genito-urinary tumours and immunotherapy.
  • Keynote lectures: these must-attend sessions will give delegates the full picture regarding the evolution of cancer research and patient care, reaching beyond individual disease types to offer thought-provoking interdisciplinary discussion including:
  • "The development of checkpoint inhibitors" by Jim Allison, Saturday, 8 October, 13:00
  • "The art of the possible: Bridging the gap between genomics and patient care?" by Emile Voest, Sunday, 9 October, 13:00
  • "The patient journey: Is cancer cure around the corner?", by Jean-Charles Soria, Monday, 10 October, 13:00
  • Onco-immunology: a fully dedicated track with more than 100 abstracts submitted, including hands-on educational sessions for practitioners, with a focus on patient selection and side-effect management.
  • Record number of abstracts submitted under the Biomarkers topic, highlighting the importance of patient selection in treatment efficacy from the early phases of drug development to the bedside.
  • Spotlight on resistance to therapy, the use of mouse models to help develop better targeted therapies and adapting clinical trials to tumour biology.
  • The latest on BRCA testing in ovarian cancer and triple-negative breast cancer.
  • Challenges and promises in the treatment of tumours of the central nervous system.
  • How to provide patients with precision medicine in the clinic - interdisciplinary patient cases to translate theory into reality.
  • A "Drugs you will be using in 2020" special symposium to share a vision of what to expect in the years ahead.
  • Cancer prevention and screening including evidence-based prevention approaches.
  • Public policy: sessions focusing on the most important public policy issues including the equitable delivery of anti-cancer drugs, the registration and use of Big Data and individual molecular profiles, and different approaches to qualify clinical benefit in oncology.

The full ESMO 2016 Congress programme is available at http://www.esmo.org/Conferences/ESMO-2016-Congress/Programme

Media registration 

ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.

Media representatives are required to observe and abide by the ESMO 2016 Media Policy

http://www.esmo.org/Conferences/ESMO-2016-Congress/Press-Media/Media-Policy

To register for the event, please fill out the Complimentary Media Registration Form

http://esmo.formstack.com/forms/media_registration_form_esmo2016

Media registration in advance is strongly recommended (deadline: Thursday, 29 September 2016).

A fully equipped ESMO Press Centre will be available to registered journalists, including a press room with technical facilities (computers, wi-fi internet, telephones, photocopier, etc.), interview rooms and storage cabinets. On-site staff will be ready to assist and facilitate one-on-one interviews with researchers and key opinion leaders throughout the Congress.

ESMO Press Programme 

The official ESMO 2016 Press Programme is being developed and will be confirmed after review and acceptance of submitted abstracts. Details will be progressively uploaded at http://www.esmo.org/Conferences/ESMO-2016-Congress/Press-Media

Meeting venue and accommodation 

The ESMO 2016 Congress will take place at the Bella Center Copenhagen, in the heart of Ørestad with its own Metro station (M1). Bella Center Copenhagen is conveniently located for both Copenhagen Airport (six kilometres) and Copenhagen city centre (eight kilometres). Further information can be found here: http://www.bellacentercopenhagen.dk/en-GB/Location/Transport.aspx

BELLA CENTER COPENHAGEN

Center Boulevard 5

DK - 2300 Copenhagen S

As Copenhagen is a highly popular tourist destination, we advise you to book your hotel accommodation as soon as possible: http://www.esmo.org/Conferences/ESMO-2016-Congress/Travel-Accommodation

We look forward to welcoming you to Copenhagen!

The ESMO Press Office Team
media@esmo.org
Tel:  +41 (0)91 973 19 04

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.